Literature DB >> 24534448

Manipulating immune cells for adoptive immunotherapy of cancer.

Phillip K Darcy1, Paul Neeson2, Carmen S M Yong3, Michael H Kershaw4.   

Abstract

The immune system can be induced to respond against cancer with some success reported in clinical trials using a range of approaches including vaccines and antibodies. In addition to these approaches, cell based therapies are demonstrating much promise as potential therapies for cancer. In cell therapies autologous patient leukocytes are isolated and manipulated in vitro before transfer back to the patient in adoptive transfer regimens. The majority of approaches utilize conventional T cells or dendritic cells, but a wide variety of other types of leukocytes exist which can possess anti-cancer activity. In this review, we present a brief overview of T cell adoptive cell transfer followed by a review of approaches using alternate lymphocyte subsets and other leukocytes including neutrophils, macrophages and eosinophils.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24534448     DOI: 10.1016/j.coi.2014.01.008

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  21 in total

Review 1.  Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Authors:  V I Seledtsov; A G Goncharov; G V Seledtsova
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.

Authors:  Bettina Weigelin; Elixabet Bolaños; Alvaro Teijeira; Ivan Martinez-Forero; Sara Labiano; Arantza Azpilikueta; Aizea Morales-Kastresana; José I Quetglas; Esther Wagena; Alfonso Rodríguez Sánchez-Paulete; Lieping Chen; Peter Friedl; Ignacio Melero
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-01       Impact factor: 11.205

3.  Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity.

Authors:  Yang Yan; Songyan Li; Tingting Jia; Xiaohui Du; Yingxin Xu; Yunshan Zhao; Li Li; Kai Liang; Wentao Liang; Huiwei Sun; Rong Li
Journal:  Tumour Biol       Date:  2015-01-28

4.  PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.

Authors:  Jiqing Sai; Philip Owens; Sergey V Novitskiy; Oriana E Hawkins; Anna E Vilgelm; Jinming Yang; Tammy Sobolik; Nicole Lavender; Andrew C Johnson; Colt McClain; Gregory D Ayers; Mark C Kelley; Melinda Sanders; Ingrid A Mayer; Harold L Moses; Mark Boothby; Ann Richmond
Journal:  Clin Cancer Res       Date:  2016-12-21       Impact factor: 12.531

5.  Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.

Authors:  Nadja Müller; Susanne Michen; Stefanie Tietze; Katrin Töpfer; Alexander Schulte; Katrin Lamszus; Marc Schmitz; Gabriele Schackert; Ira Pastan; Achim Temme
Journal:  J Immunother       Date:  2015-06       Impact factor: 4.456

6.  Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell.

Authors:  Jiang Chen; Xiao-Zhong Guo; Hong-Yu Li; Di Wang; Xiao-Dong Shao
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-02

Review 7.  Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review.

Authors:  Daniel M Geynisman; Chun-Ru Chien; Fabrice Smieliauskas; Chan Shen; Ya-Chen Tina Shih
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Acceleration of tumor growth due to dysfunction in M1 macrophages and enhanced angiogenesis in an animal model of autoimmune disease.

Authors:  Tomoyuki Kondo; Takaaki Tsunematsu; Akiko Yamada; Rieko Arakaki; Masako Saito; Kunihiro Otsuka; Satoko Kujiraoka; Aya Ushio; Mie Kurosawa; Yasusei Kudo; Naozumi Ishimaru
Journal:  Lab Invest       Date:  2016-01-25       Impact factor: 5.662

9.  Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.

Authors:  Nan Guo Ring; Dietmar Herndler-Brandstetter; Kipp Weiskopf; Liang Shan; Jens-Peter Volkmer; Benson M George; Melanie Lietzenmayer; Kelly M McKenna; Tejaswitha J Naik; Aaron McCarty; Yunjiang Zheng; Aaron M Ring; Richard A Flavell; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-20       Impact factor: 11.205

10.  Antigen-loaded dendritic cells triggers a specific cytotoxic T lymphocytes immune response against hepatocellular carcinoma: in vitro study.

Authors:  N E El-Ashmawy; E A El-Zamarany; E G Khedr; H A El-Bahrawy; O A El-Feky
Journal:  Clin Transl Oncol       Date:  2018-10-27       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.